Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207363 · ClinicalTrials.gov registry record · Phase 4
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
A Phase 4 study of Hepatitis C, sponsored by Brooke Army Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 610
- Enrollment target
- 1
- Study location
NCT00207363 is a Phase 4 study of Hepatitis C that has completed, run by Brooke Army Medical Center. The registered enrollment target is 610 participants, below the 1,884-participant average among 106 other Hepatitis C trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00207363, a Phase 4 study of Hepatitis C, has completed, sponsored by Brooke Army Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 610 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see which of two doses of PEG (polyethylene glycol) interferon alfa-2b in combination with Ribavirin for 48 weeks is more effective at elimination of hepatitis C. The primary objective of this study is to compare the efficacy of Induction PEG-Interferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol) to standard PEG-Interferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol) in patients with chronic hepatitis C.
Conditions Studied
Interventions
- DRUG Ribavirin, Peg interferon alfa 2b
- DRUG induction therapy
Study Locations (1)
Texas
- Brooke Army Medical Center - Fort Sam Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2002-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207363
The ClinicalTrials.gov registry entry for NCT00207363 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 610 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,884-participant average among 106 other Hepatitis C trials with a reported enrollment target (68% lower). The listed sponsor is Brooke Army Medical Center, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Ribavirin, Peg interferon alfa 2b is the first listed.
NCT00207363 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00207363 about?
NCT00207363 is a clinical study titled "Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC". The purpose of this study is to see which of two doses of PEG (polyethylene glycol) interferon alfa-2b in combination with Ribavirin for 48 weeks is more effective at elimination of hepatitis C. The primary objective of this study is to compare the efficacy of Induction PEG-Interferon alfa-2b (PEG-...
What is the current status of trial NCT00207363?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 610 participants. The study started on 2002-02. Estimated completion is 2010-01.
What conditions does trial NCT00207363 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00207363?
The interventions under investigation include: Ribavirin, Peg interferon alfa 2b (DRUG), induction therapy (DRUG).
Who is sponsoring clinical trial NCT00207363?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00207363 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
-
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.